- As Previously Announced, Richard A. Gonzalez Retires as
Chief Executive Officer to Become Executive Chairman
- Robert A. Michael Joins AbbVie Board of Directors
NORTH
CHICAGO, Ill., July 1, 2024
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that
Robert A. Michael has assumed the
role of chief executive officer (CEO) and has joined AbbVie's Board
of Directors, effective today. As previously announced, Mr. Michael
succeeds Richard A. Gonzalez, who
has served as CEO since the company's inception in 2013. Mr.
Gonzalez has become executive chairman of the board of
directors.
Mr. Michael previously served as president and chief operating
officer of AbbVie and has been a longstanding member of AbbVie's
Executive Leadership Team. In the role of president and chief
operating officer, Mr. Michael was responsible for global
commercial operations, finance, corporate human resources, global
operations, business development and corporate strategy for the
company. He was previously appointed vice chairman and president in
2022, vice chairman, finance and commercial operations in 2021 and
chief financial officer in 2018. Mr. Michael has more than 31
years of experience including leadership roles across multiple
businesses, including pharmaceuticals, aesthetics, diagnostics,
diabetes care and nutrition. He began his career with Abbott as a
member of the financial development program.
"It is an honor to step into the CEO role at AbbVie and build on
Rick's achievements," said Robert A.
Michael, chief executive officer, AbbVie. "Our mission to
deliver innovative medicines to patients has never been more
critical, and the opportunities before us are exciting. I look
forward to working with our approximately 50,000 employees to drive
the next phase of AbbVie's growth. I am committed to preserving our
strong culture and delivering a remarkable impact for our patients,
employees, shareholders and communities. I would like to thank Rick
for his strong leadership for the past 11 years, and I am grateful
he will continue to contribute to AbbVie as executive
chairman."
"The board and I have great confidence in Rob, and we know that
his combination of experience, skills and vision uniquely prepares
him to lead AbbVie," said Richard A.
Gonzalez, executive chairman, AbbVie. "We have the right
leadership team in place, the strategy and the financial foundation
to ensure a bright future for AbbVie. It has been a privilege to
serve with the people of AbbVie as CEO, and I look forward to
working alongside Rob and the AbbVie Board of Directors to continue
to deliver on our promise to patients around the world."
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
and solutions that solve serious health issues today and address
the medical challenges of tomorrow. We strive to have a remarkable
impact on people's lives across several key therapeutic areas –
immunology, oncology, neuroscience, and eye care – and products and
services in our Allergan Aesthetics portfolio. For more information
about AbbVie, please visit us at www.abbvie.com. Follow
@abbvie on LinkedIn, Facebook, Instagram, X
(formerly Twitter), and YouTube.
AbbVie Forward-Looking Statements
Some statements in this news release are, or may be
considered, forward-looking statements for purposes of the Private
Securities Litigation Reform Act of 1995. The words "believe,"
"expect," "anticipate," "project" and similar expressions and uses
of future or conditional verbs, generally identify forward-looking
statements. AbbVie cautions that these forward-looking statements
are subject to risks and uncertainties that may cause actual
results to differ materially from those expressed or implied in the
forward-looking statements. Such risks and uncertainties include,
but are not limited to, challenges to intellectual property,
competition from other products, difficulties inherent in the
research and development process, adverse litigation or government
action, and changes to laws and regulations applicable to our
industry. Additional information about the economic, competitive,
governmental, technological and other factors that may affect
AbbVie's operations is set forth in Item 1A, "Risk Factors," of
AbbVie's 2023 Annual Report on Form 10-K, which has been filed with
the Securities and Exchange Commission, as updated by its
subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no
obligation, and specifically declines, to release publicly any
revisions to forward-looking statements as a result of subsequent
events or developments, except as required by law.
View original
content:https://www.prnewswire.com/news-releases/robert-a-michael-assumes-role-as-abbvie-chief-executive-officer-302186870.html
SOURCE AbbVie